Biomedical Advanced Research and Development Authority (BARDA), which evolved out of the biodefense-focused Project BioShield, has moved beyond simply funding drugs and devices that might be used in the event of terrorism. Read More
With $24 million in series B financing, Aldea Pharmaceuticals Inc. will gather more safety data this year and in the second half of 2015 start a phase II trial in acute alcohol intoxication with its lead candidate, AD-6626, based on technology licensed from Stanford University. Read More
SHANGHAI – Innovent Biologics Inc. and its staff of 170 took occupancy of its $140 million facility in Suzhou's Biobay Industrial Park this month. The impressive facility designed with ancient fengshui principles in mind, houses two state-of-the-art 1,000-liter bioreactors. Read More
Using deep sequencing of candidate genes, researchers have identified mosaic mutations – mutations that exist in only some of the body's cells, because they arose as a result of a copying error during cell division rather than being present in the sperm or egg – in about a third of patients with malformations of the cerebral cortex. Read More
SHANGHAI – Newly minted Zai Lab Ltd., of Shanghai, has made its eagerly awaited debut announcement, obtaining global rights to two Sanofi SA preclinical compounds for chronic respiratory diseases. Read More
SHANGHAI – Privately held Huya Bioscience International, of San Diego, has signed a strategic partnership with the Changzhou Center for Biotech Development (CZCBD) for the advancement of innovative drug and biomarker candidates. Read More
Bioniche Life Sciences Inc., of Belleville, Ontario, said it filed a preliminary short form prospectus with securities regulatory authorities in each of the provinces in Canada, excluding Quebec, in connection with an overnight marketed offering with Dundee Securities Ltd. acting as the sole agent. The offering will consist of units, with the price per unit to be determined in the context of the market. Read More
Sucampo Pharmaceuticals Inc., of Bethesda, Md., said its subsidiary, Sucampo AG, revised its exclusive global manufacturing and supply agreement with its manufacturing and development partner, R-Tech Ueno Ltd., of Tokyo, for clinical and commercial supplies of Amitiza (lubiprostone) in most global markets. Read More
Aastrom Biosciences Inc., of Ann Arbor, Mich., said results from an open-label phase IIa study of ixmyelocel-T, its cell therapy for treating advanced heart failure due to ischemic dilated cardiomyopathy (DCM), were published in Circulation Research. Read More
Despite the fact that the Ebola virus has hijacked the headlines, many other infectious agents remain concerns for the World Health Organization and others who deal with emerging pathogens full-time. Read More
